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Factors Influencing Insulin Secretion From Encapsulated Islets
Bart J. de Haan, Marijke M. Faas, and Paul de Vos
Immunoendocrinology, Department of Pathology and Laboratory Medicine, Section of Medical Biology, University of Groningen,
Hanzeplein 1, 9700 RB Groningen, The Netherlands
Adequate regulation of glucose levels by a microencapsulated pancreatic islet graft requires a minute-to-
minute regulation of blood glucose. To design such a transplant, it is mandatory to have sufficient insight
in factors influencing the kinetics of insulin secretion by encapsulated islets. The present study investigates
factors influencing the glucose-induced insulin response of encapsulated islets in vitro. We applied static
incubations and did the following observations. (i) Small islets (90–120 µm) showed a similar instead of a
lower glucose-induced insulin response, suggesting that inclusion of only small islets, which are associated
with lower protrusion and failing rates, has no consequences for the functional performance of the graft. (ii)
A capsule diameter of 800 µm showed identical rather than lower glucose-induced insulin responses as
smaller, 500-µm capsules. (iii) Capsule membranes constructed with a conventional permeability interfered
with diffusion of insulin, as illustrated by a lower response of islets in capsules with a 10-min poly-L-lysine
(PLL) membrane than islets in capsules with a 5-min PLL membrane. (iv) Irrespective of the tested porosity,
the capsules provided sufficient immunoprotection because the 10-min PLL membranes did block diffusion
of the cytokines IL-1β (17 kDa) and TNF-α (70 kDa) while the 5-min PLL membranes interfered with the
diffusion of the vast majority of the cytokines. We conclude that capsules containing small islets (90–120
µm) and a membrane with a lower permeability than routinely applied is preferred in order to obtain a graft
with adequate glucose-induced insulin responses.
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INTRODUCTION lated grafts (1,8,13,21,23), it has been the focus of not
more than a few studies (1,6,8,11,26). The diffusion ki-
netics for encapsulated islets has been shown to be dif-Immunoprotection involves envelopment of tissue in
a semipermeable membrane to protect donor cells against ferent from islets in the native pancreas. A delay in insu-
lin response after a glucose stimulus has been observedantibodies and cytotoxic cells of the host immune sys-
tem. This immunoprotection by encapsulation allows for both in vitro (33) and in vivo (1,6,11). Plausibly, this
delayed insulin response is caused by interference of thesuccessful transplantation of cells in the absence of im-
munosuppression. A commonly used procedure for im- capsule membrane with optimal exchange of glucose
and insulin (26). The rate of diffusion over the capsulemunoprotection is microencapsulation of tissues in algi-
nate-poly-L-lysine (PLL)-based capsules as originally membrane is determined by surface/volume ratio of the
capsules. This implies that when the capsule diameter isdescribed by Lim and Sun (19). During recent years,
important advances have been made with this technol- small the ratio and thus the diffusion rate will be higher.
Therefore, small capsule diameters are preferred forogy. The first allotransplantations in humans with encap-
sulated parathyroid cells and pancreatic islets have been transplantation of encapsulated islets. Yet, a major ob-
stacle in application of small-diameter capsules is thesuccessfully performed (15,24). Also, successful xeno-
transplantation of islet grafts has been shown in both high amount of protruding islets, which cause rejection
and subsequent failure of the graft (5,7). A conceivablechemically induced and autoimmune diabetic rodents
(13,21,34), dogs (23,32), and monkeys (25,38). approach to reduce protrusion is the use of only small
islets for encapsulation. However, it is not knownA major requirement for clinical application of en-
capsulated pancreatic islets is that the graft adequately whether this has a drawback on the function of the graft
because small islets are assumed to produce less insulinregulates glucose levels. Although this is a factor that
may contribute to the variable success rates of encapsu- than large islets.
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In the present study we compare the glucose-induced verted into droplets using an air-driven droplet generator
as previously described (37). Subsequently, the alginateinsulin response of encapsulated islets containing islets
with different sizes. In addition, we identified some other droplets were transformed to alginate beads by gelling
in a 100 mM CaCl2 (10 mM HEPES, 2 mM KCl) solu-factors influencing the glucose-induced insulin response
of encapsulated pancreatic islets. Identification of such tion for at least 5 min (14). After gelation the beads had
a diameter of 450–550 µm when 800-µm capsules werefactors appears mandatory for modifying the alginate-
PLL microencapsulation procedure in order to allow ad- produced and 350–400 µm when 500-µm capsules were
produced. The Ca-alginate beads were suspended for 3equate responses of the microencapsulated tissue.
min in KRH containing 2.5 mmol/L CaCl2. A PLL mem-MATERIALS AND METHODS brane was formed by suspending the alginate beads in
Animals 0.1% PLL solution for 5 or 10 min (poly-L-lysine-HCl,
MW: 22,000, Sigma). Nonbound PLL was removed byMale inbred Albino Oxford (AO/G) rats were ob-
three successive washings during 3 min with Ca2+-freetained from Harlan CPB (Zeist, The Netherlands) or the
KRH containing135 mM NaCl. The outer alginate layerCentral Animal Laboratory of Groningen. NHI guide-
was subsequently applied by 5-min incubation in 10lines for the care and use of laboratory animals were ap-
times diluted alginate solution.plied.
Insulin Secretion During Glucose ChallengeIslet Isolation
In static incubation experiments, islets were tested inIslets were isolated as previously described (36).
four separate samples of 10 islets each. To minimize theBriefly, under ether anesthesia, the abdomen was opened
variability of the mean insulin responses, we meticulouslyand the common bile duct was cannulated under non-
selected islets with diameters between 90 and 120 µm.sterile conditions. The donor pancreas was distended
In some experiments we used other islet diameters, aswith 10 ml sterile Krebs-Ringer-HEPES supplemented
indicated in the Results section. The encapsulated isletswith 25 mmol/L HEPES buffer (KRH) containing 10%
were preincubated for 45 min in 2 ml Krebs-Ringer-bicar-bovine serum albumin (BSA). Subsequently, the pan-
bonate (KRB), gassed with 95% O2 and 5% CO2, contain-creas was excised and brought into a laminar flow cabi-
ing 0.25% BSA and 2.75 mM glucose. The quantitativenet. All further procedures were performed under sterile
insulin secretion was then assessed by three consecutiveconditions.
incubations of (i) 45 min in 2.75 mM glucose in KRB,The pancreas was chopped and digested using a two-
(ii) 45 min in 16.5 mM glucose in KRB, and (iii) 45 minstage incubation of 20 min at 37°C with successively
in 2.75 mM glucose in KRB. These incubations were1.0 and 0.7 mg/ml collagenase (Sigma type XI, Sigma,
performed in a Labline metabolic incubator at a stirringSt. Louis, MO, USA). Islets were separated from exo-
rate of 120 cycles/min at 37°C. At the end of each incu-crine tissue by centrifugation over a discontinuous dex-
bation, the incubation media were removed and frozentran gradient (30) and further purified by handpicking.
for insulin determination. The insulin secretory responsesThe diameters were measured with a dissection mi-
were expressed as nanogram of insulin ml−1 10 islets−1croscope with a fluorescent illuminator (Bausch and
45 min−1.Lomb BVB-125, and 31-33-66) equipped with an ocular
The incubations with varying experimental condi-micrometer with an accuracy of 25 µm. For determina-
tions were simultaneously performed with one batch oftion of the diameters we measured at least 150 islets.
islets on 1 day. These incubations were always performedIslets were cultured before encapsulation to reduce
threefold to reduce variations in the individual experi-contamination of the grafts with exocrine tissue, ducts,
ments. The experiments were repeated five to eight times.or damaged cells. They were cultured in nontreated petri
dishes (Greiner, Alphen a/d Rijn, The Netherlands) in
Cell Cultureportions of 100 islets per 25 cm2 for 19–44 h in RPMI-
The nr8383 macrophage cell line was cultured in 60-1640 [containing 10% fetal calf serum (FCS, Gibco,
ml culture flasks containing RPMI-1640 with 10% FCS,Breda, The Netherlands), 8.3 mmol/L glucose, 10 mmol/
8.3 mmol/L glucose, 10 mmol/L HEPES, and 1% peni-L HEPES, and 1% penicillium/streptomycin] at 37°C in
cillium/streptomycin. The cultures were kept at 37°C inhumidified air containing 5% CO2.
humidified air containing 5% CO2.
Encapsulation The nr8383 macrophage cell line was encapsulated in
a novel two-step procedure. First, the cells were immo-After culture, islets were washed three to five times
with RPMI containing 10% FCS and were subsequently bilized in a small alginate bead of 200 µm. Therefore,
LPS-stimulated (0.5 µg/ml for 1 h) nr8383 cells weresuspended in sterile filtered (0.2 µm filtration) 3–3.3%
purified alginate solution. The alginate solution was con- mixed in a ratio of 30 million cells per 1 ml alginate.
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The alginate/nr8383 suspension was converted into drop- tions tested showed identical instead of a size-dependent
difference in their glucose-induced insulin response. Thelets using an air-driven droplet generator (37). Droplets
of approximately 200 µm were produced and allowed to 210–300-µm islets produced slightly more insulin after
stimulation with glucose, but this never reached statisti-gel for 5 min in 100 mM CaCl2 (10 mM HEPES, 2 mM
KCl). High numbers of cells were protruding from these cal significant difference.
Surprisingly, the presence of a capsule around the is-small beads. In the second step, the cells containing Ca-
alginate beads were resuspended in alginate for encapsu- lets reduced both the basal and the stimulated glucose-
reduced insulin response. Theoretically, this reduction inlation without protrusion of cells. To this end, the 200-
µm Ca-alginate beads were suspended in a 2 ml 3.4% insulin response can be caused by two factors. First, the
encapsulation procedure may have interfered with thealginate solution for a second envelopment in beads. The
alginate containing immobilized nr8383 cells was con- viability of the islet tissue because reportedly (14) some
steps in the procedure interfere with adequate functionverted into droplets and allowed to gel for 5 min in 100
mM CaCl2 (10 mM HEPES, 2 mM KCl). After gelation of the islets. Secondly, and more plausibly, the presence
of the capsule may have interfered with the exchange ofthe beads had a diameter of 550–600 µm. The beads
were subsequently subjected to the encapsulation proce- glucose and insulin over the capsule membrane (3,8,33).
To investigate whether the observed reduction in insulindure as described in the encapsulation section.
To test the permeability of the capsules for the response was caused by a harmful step in the encapsula-
tion procedure or by the presence of a capsule aroundnr8383-derived IL-1β and TNF-α, the beads were coated
with three different PLL time periods to obtain three the islet we removed the capsule. To this end, the cap-
sule was manually disrupted and removed before the in-different permeabilities. Therefore, the beads were di-
vided into three groups and incubated for 0, 5, and 10 sulin-secreting capacity of the so-called deencapsulated
islets were tested. As shown in Figure 3, the insulin re-min with 0.1% PLL.
The experiments were always performed in triplicate sponse of deencapsulated islets was restored and statisti-
cally significantly higher (p < 0.02) than that of isletsto reduce variations in the individual experiments. To
this end, three separate samples of 100 capsules contain- still enveloped within the capsules.
Next, we investigated whether the interference of theing macrophages were incubated in 24-well plates and
cultured for 48 h in RPMI-1640 with 10% FCS, 8.3 capsule membrane with adequate glucose-induced insu-
lin responses was caused by the relative large capsulemmol/L glucose, 10 mmol/L HEPES, and 1% penicil-
lium/streptomycin at 37°C in humidified air containing size of 800 µm because the capsule size has been re-
ported to be an important factor influencing the glucose-5% CO2. At the end of the experiments the incubation
media were removed for assessment of IL-1β and TNF- induced insulin response of encapsulated islets (Fig. 4).
Therefore, we tested and compared islets encapsulatedα production. Data are expressed as ng/ml.
in large (800-µm) capsules and islets encapsulated in
Determinations small (500-µm) capsules. In these tests the capsules
Insulin was determined by a radioimmunoassay for were incubated with 5 min of PLL instead of the 10 min
rat insulin (Linco, St. Charles, MO, USA) using rat insu- applied in the experiments in Figure 2.
lin as a standard. IL-1β and TNF-α were determined by As shown in Figure 5, the basal and stimulated in-
ELISA (R&D, Abingdon, UK) using rat IL-1β and rat sulin secretion of islets in 500- and 800-µm capsules
TNF-α as a standard. showed similar if not identical insulin levels. Evidently,
the reduction in capsule diameter from 800 to 500 µm
Statistical Analysis did not bring about the expected increase in secretory
Results are expressed as mean ± SEM. Statistical capacity of encapsulated islets.
comparisons were made with the Mann-Whitney U-test. A surprising observation in the previous experiment
A value of p < 0.05 was considered statistically signifi- was done when we compared the quantitative insulin
cant. secretion of the encapsulated islets in the set of experi-
ments in Figure 5 with those of the first set (Fig. 2). In
RESULTS the experiments presented in Figure 5 we found a basal
and stimulated insulin secretion of encapsulated islets thatThe diameters of isolated islets varied between 60
and 300 µm (Fig. 1). The effect of the islet diameter on was not lower but identical to that of free islets (106 ±
9 vs. 98 ± 11 for basal, and 308 ± 29 vs. 296 ± 42 forthe insulin secretion before and after encapsulation was
tested with diameter populations of 90–120, 150–180, stimulated). Because in the previous experiments we had
set the incubation time with PLL to 5 min instead of theand of 210–300 µm because these islet diameters were
present in sufficient numbers for static incubation test- routinely applied 10 min, we questioned whether the
PLL incubation time was an unidentified factor deter-ing. As shown in Figure 2, the three diameter popula-
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Figure 1. Distribution of the islet diameters in a collagenase digested pancreas (n = 12). Values
represent mean ± SEM.
mining the capacity of encapsulated islets to respond ad- with 5-min PLL incubation could be explained by a low-
ered permeability of the capsules. Therefore, the effectequately to a glucose load.
Therefore, we tested and compared in a next set of of the PLL reaction time on the diffusion of low and
high molecular molecules was investigated with the cy-experiments (i) free islets, (ii) islets in capsules treated
for 5 min with PLL, and (ii) islets in capsules treated tokines IL-1β (17 kDa) and TNF-α (70 kDa). These per-
meability testings were done by assessing the diffusionfor 10 min with PLL. As shown in Figure 6, free islets
and islets in capsules treated for 5 min with PLL elicited of these cytokines from encapsulated nr8383 macro-
phages. As shown in Figure 7, we found that decreasingsimilar amounts of insulin during incubation in both low
and high glucose while islets in capsules treated for 10 the conventional permeability of the membrane by re-
ducing the PLL incubation time 5 min, the porosity ofmin with PLL showed a profound reduced response.
Finally, we questioned whether the improved results the membrane for IL-1β increased from <4% to 26%,
Figure 2. Glucose-induced insulin response of free (n = 6, filled bars) and microencapsulated
(n = 6, open bars) rat islets with varying diameters. Alginate-PLL capsules were 800 µm. Values
represent mean ± SEM.
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Figure 3. Glucose-induced insulin response of microencapsulated (n = 5, left) rat islets and islets
from which the microcapsule (i.e., deencapsulated) was removed (n = 6, right). Alginate-PLL cap-
sules were 800 µm. Values represent mean ± SEM.
and for TNF-α from <2% to 28%, illustrating a pro- the islet diameters or capsule diameter in the routinely
applied 500–800-µm range.found effect of this seemingly minor modification in
PLL reaction time on the permeability of the capsules. The finding that the glucose-induced insulin response
of encapsulated islet is not influenced by the capsule’s
DISCUSSION diameter does not corroborate the findings of Chichepor-
tiche et al. (3). These authors observed an almost com-To provide a minute-to-minute regulation of blood
glucose levels by transplanted microencapsulated islets, plete abrogation of the glucose-induced insulin response
when the capsules size was increased from 300 to 800the kinetics of insulin secretion by encapsulated islets
are of crucial importance. This study clearly demonstrates µm. A possible explanation for this discrepancy in ob-
servations is the location of the islets in the capsules,that the responses of encapsulated islets are influenced
by the permeability of the capsule membrane and not by which was more peripheral in the capsules applied in
the present study (12). This implies a shorter diffusion
distance for both glucose and insulin over the capsule
membrane and, therefore, may facilitate the responses of
the islets in the large, 800-µm capsules.
During our comparison of the glucose-induced insu-
lin responses of islets with different sizes, we surpris-
ingly found similar instead of size-dependent differences
in insulin secretion. This lack of effect of islet size on
insulin secretion could probably be explained by the fact
that in isolated islets the glucose is penetrating the islets
by passive diffusion instead of by active transport to
each individual islet cell by the bloodstream. This pas-
sive diffusion of glucose is predictably less efficient than
active transport to the islet cells by the bloodstream as in
normal, vascularized islets in the native pancreas (2,20).
Consequently, the glucose around large isolated islets
will only stimulate islet cells in the periphery rather than
the more centrally located islet cells.Figure 4. Islets in capsules of 500 and 800 µm. Note the large
Our observations that islets of different sizes showdifference in volume of the capsules (original magnification
×10). similar responses confirm the findings of Colella et al.
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Figure 5. Effect of capsule diameter on glucose-induced insulin response of microencapsulated rat
islets in capsules of 500 µm (n = 8, left) and 800 µm (n = 8, right) Values represent mean ± SEM.
(4), who observed a similar insulin secretory response cal response but an adaptation of the basal insulin secre-
tion to a continuous change in environment instead ofin spite of a twofold difference in DNA content. How-
ever, our observations do not corroborate the findings of an increased response to a sudden change in metabolic
demand. Also, the time period in which the challenge isJahr et al. (16) and Reaven et al. (22). This could be
explained by a difference in the experimental set up. performed may contribute to the difference in findings.
The magnitude of the response in static incubations isJahr et al. studied the insulin secretion of islets only at
a continuous high glucose level instead of investigating dependent on diffusion of glucose into the islets. This
implies that this process is complete in a shorter periodthe responses during glucose challenge at low and a sub-
sequent high glucose level (16). This is essential because of time in small than in large islets and may explain
why in static incubation systems with short incubationthe former does not necessarily represent the physiologi-
Figure 6. Effect of permeability of microcapsules on glucose-induced insulin response of microen-
capsulated rat islets. Free islets (n = 6, left), islets in capsules with low permeability induced by 5-
min incubation in PLL (n = 6, middle), and islets in capsules with routine, commonly applied
permeability by 10-min incubation in PLL (n = 6, right). Values represent mean ± SEM.
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Figure 7. TNF-α and IL-1β release of encapsulated LPS-stimulated nr8383 macrophages (n = 4) with different permeabilities of
the capsules by varying the PLL incubation times. Values represent mean ± SEM.
periods small islets respond with a similar insulin secre- the glucose-induced insulin response by decreasing the
PLL incubation time only 5 min is rather surprising, be-tion, because not all cells in the larger islets have partici-
pated. Consequently, when the incubations are performed cause our and other previous studies have shown that
capsules treated with similar incubation times with simi-for a longer period of time a higher response is to be
expected. This argumentation is supported by the obser- lar types of PLL molecules are permeable for substances
up to 120 kDa (5,17,31). Notably, previous studies onvations of Reaven et al. (22), showing a somewhat higher
response of the larger islets when the authors applied a permeability of capsules were performed with linear,
nonionic molecules (mostly dextran), which have diffu-33% longer incubation period of 60 min instead of the
conventional 45 min. In our experimental design we ap- sion characteristics far different from that of nonlinear
and charged proteins such as insulin. Our present dataplied a 45-min incubation period because in vivo, in suc-
cessful graft recipients, glucose levels usually return to suggest that it is mandatory to study permeability of cap-
sules by assessing the diffusion of relevant bioactivebasal in this time period (9).
The observation that encapsulated small, 90–120-µm factors rather than by measuring exchange of irrelevant
model molecules such as dextran.islets show similar instead of lower glucose-induced in-
sulin responses than 150–180- and 210–300-µm islets The above also holds for diffusion of molecules that
are involved in rejection of islets such as chemokinessuggests that the inclusion of only small islets in encap-
sulated grafts will have no consequences for the func- and cytokines. Based on the molecular weight of the
cytokines, it has been assumed that conventional immu-tional performance of the grafts. This is a pertinent con-
sideration because small islets are associated with less noisolating capsules cannot prevent the entry of the ma-
jority of chemokines and cytokines (18). In the presentprotrusion (5,7,27) and, therefore, a lower rate of failing
encapsulated islets. Another advantage of application of study, we showed for the first time that in spite of their
low molecular weight the cytokines IL-1β (17 kDa) andsmall islets is the reduction of problems associated with
insufficient nutrition and central necrosis of the encapsu- TNF-α (70 kDa) cannot readily diffuse over the capsule
membrane. Capsules membranes treated for 10 min withlated islets with sizes larger than 150 µm (10). This ne-
crosis has been shown to be a major cause of failure PLL showed virtually no permeability for IL-1β and
TNF-α while capsule membranes treated for 5 min al-of encapsulated grafts (8,10). However, the effects of
application of only the small rather than the large islets lowed passage of only a portion of less than 30% of
the total amount of cytokines. After deencapsulating theon longevity of encapsulated islet grafts requires some
further research considerations because longevity of the macrophages from the 5- and 10-min PLL-treated cap-
sules, the cytokine levels reached the values of the non-graft is determined by the size of the graft volume
(28,29), which is mainly determined by the number of treated PLL capsules (data not shown). This illustrates
that the PLL treatment does not interfere with the cyto-large islets in the transplant (29,35,36).
The dramatic effect of lowering the permeability on kine production by the macrophages but that the mem-
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